LIFE aTyr Pharma

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2021 financial results and provide a corporate update after the market close on Wednesday, November 10, 2021. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:

Wednesday, November 10th @ 5:00 pm EST / 2:00 pm PST

Domestic: 844-358-9116

International: 209-905-5951

Conference ID: 9134928

Webcast:

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit .

Contact:

Ashlee Dunston

Director, Investor Relations and Corporate Communications

 



EN
03/11/2021

Underlying

LIFEaTyr Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on aTyr Pharma

 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Confere...

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference, which is scheduled to take place December 2 – 4, 2025, in New York, NY. Details of the presentation appears below: Conference:...

November 10, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporat...

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update  Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.  Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEG...

November 6, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study ...

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King’s Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- ...

September 30, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of ...

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo...

September 15, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635...

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr’s common stock, each with an exercise price of $5.71 per share, which is eq...

September 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch